Health & Fitness
Sat, March 24, 2012
TEWKSBURY, Mass.--([ BUSINESS WIRE ])--[ Cambridge Heart, ] Inc. (OTCBB: CAMH), a developer of non-invasive diagnostic tests for cardiac disease, today announced that its [ Microvolt T-Wave Alternans ]a" (MTWA) test received reimbursement coverage from Japanas Ministry of Health, Labor and Welfare (MHLW). Effective April 1, 2012, the MTWA Test will be reimbursed for patients who are considered at risk for lethal arrhythmias including, but not limited to, patients with a history of heart attack, cardiomyopathy and Brugada syndrome.
"This decision highlights the valuable role that MTWA can play in managing a patientas risk for sudden cardiac arrest"
Commenting on the decision, Dr. Takanori Ikeda, Professor of Medicine at Toho University Medical Center, said, aWe are very pleased with the reimbursement decision on MTWA testing. A large body of clinical evidence supports the predictive value of the test which can now be used more broadly to help identify and manage the risk of life-threatening arrhythmias.a
Cambridge Heart markets its MTWA technology in Japan through its partnership with Fukuda Denshi Corporation, one of Japanas leading and most active medical device and technology companies, which has already established an MTWA user base in the country , noted Ali Haghighi-Mood, Cambridge Heart President and CEO.
aThis decision highlights the valuable role that MTWA can play in managing a patientas risk for sudden cardiac arrest,a Haghighi-Mood said. aGaining reimbursement coverage in Japan, which enjoys one of the most advanced healthcare systems in the world, is an important milestone for our MTWA technology and another indicator that the value of MTWA testing is being recognized around the world. We look forward to working closely and strategically with our distribution partner in Japan to further expand that market and maximize the value of the relationship.a
About Cambridge Heart, Inc.
Cambridge Heart develops and commercializes non-invasive diagnostic tests for cardiac disease, with a focus on identifying those at risk for sudden cardiac arrest (SCA). The Companyas products incorporate proprietary Microvolt T-Wave Alternans measurement technologies, including the patented Analytic Spectral Method and ultrasensitive disposable electrode sensors. The Companyas MTWA test, originally based on research conducted at the Massachusetts Institute of Technology, is reimbursed by Medicare under its National Coverage Policy.
Cambridge Heart, founded in 1990, is based in Tewksbury, MA. It is traded on the Over-The-Counter Bulletin Board (OTCBB) under the symbol CAMH.OB.
[ http://www.cambridgeheart.com ].
Statements contained in this press release that are not purely historical are forward-looking statements.In some cases, we use words such as abelievesa, aexpectsa, aanticipatesa, aplansa, aestimatesa, acoulda, and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements.These forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties.Actual results may differ materially from those indicated by these forward-looking statements.Factors that may cause or contribute to such differences include failure to obtain or maintain adequate levels of government and third-party reimbursement for use of our MTWA test and other factors identified in our most recent Annual Report on Form 10 K under aRisk Factorsa, which is on file with the SEC and available at [ www.EDGAR.com ].In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent date.While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so except as may be legally necessary, even if our estimates should change.
